Hoerter Steven L.
SEC-identified person · CIK 1533451 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| C4 Therapeutics, Inc. CCCC | Director | filed 2024–2026 |
| MBX Biosciences, Inc. MBX | Director | filed 2025–2026 |
| Oric Pharmaceuticals, Inc. ORIC | Director | filed 2021–2026 |
| Deciphera Pharmaceuticals, Inc. NA | Director · President and CEO | filed 2018–2024 |
| Constellation Pharmaceuticals INC CNST | Director | filed 2018–2021 |
| Agios Pharmaceuticals, INC. AGIO | Chief Commercial Officer | filed 2016–2019 |
| Ignyta, Inc. RXDX | Director | filed 2016–2018 |
| Clovis Oncology, Inc. CLVS | See Remarks | filed 2011–2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.